CECO Environmental Corp. (NASDAQ: CECO) has surged in recent months, nearing its yearly high. With the mid-cap clean tech firm now trading near fair value, we analyze whether investors have missed the bargain window or if strategic entry points remain.
While index funds offer market-average returns, picking the right stock can yield significantly more. Itron, Inc. (NASDAQ: ITRI) has proven just that, delivering a 71% return to shareholders over the past three years—outperforming broader indices—as it transitioned to profitability. However, recent headwinds have tempered the rally, raising questions about its near-term trajectory.
The UK pharmaceutical giant AstraZeneca begins trading ordinary shares on the New York Stock Exchange today, a significant upgrade from its previous Nasdaq ADR listing. This move underscores the company's strategic rebalancing towards the United States, its largest market, and raises questions about the long-term relevance of its London listing.
ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.
Cardiac monitoring specialist iRhythm has finalized a significant corporate restructuring, creating a new parent company to serve as its publicly listed entity on Nasdaq. The move is seen as a strategic step to streamline governance and provide operational flexibility as the company expands its AI-driven health platform.
The Marzetti Company (NASDAQ:MZTI) is set to report fourth-quarter earnings before Tuesday's market open. Investors will scrutinize whether the maker of dressings and sauces can maintain its recent revenue beats amid a projected slowdown in growth and persistent margin pressures.
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...
Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) have surged over 50% in the last three months, reigniting debate over its fair value and the risks tied to its lead drug OJEMDA and a pivotal upcoming data readout.
InterDigital (NASDAQ: IDCC) has laid out an ambitious financial roadmap for fiscal year 2026, forecasting revenues up to $775 million. The outlook is supported by a newly inked licensing agreement with LG Electronics and a key smartphone renewal, signaling strong momentum in its patent portfolio.
B. Riley analyst Craig Ellis has upgraded Rigetti Computing (NASDAQ: RGTI) from 'Neutral' to 'Buy', maintaining a $35 price target. The upgrade follows the company's announcement of an $8.4 million order to supply a 108-qubit quantum computer to India's premier R&D agency, C-DAC, providing clearer visibility into its 2026 commercial trajectory.
USA Rare Earth Inc. (NASDAQ: USAR) sees its price target significantly raised by Canaccord Genuity and Benchmark following a landmark $1.6 billion commitment from the U.S. CHIPS Program, accelerating its plans to build a domestic rare earth supply chain.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
South Plains Financial (NASDAQ: SPFI) announces an increased quarterly dividend to $0.17 per share, reflecting strong earnings growth and a conservative payout strategy. While the yield remains modest, analysts highlight the company's potential for sustained dividend expansion.
Independent Bank Corporation (NASDAQ: IBCP) announces a dividend increase to $0.28 per share, continuing its decade-long track record of shareholder returns. Analysts highlight the payout's sustainability amid solid earnings growth projections.
In a significant industry pivot, Nasdaq-listed Bit Digital announces plans to completely exit Bitcoin mining, citing capital inefficiency and redirecting focus to Ethereum infrastructure and AI. This move follows a broader trend of crypto firms abandoning mining operations post-halving and amidst the AI boom.
Karat Packaging Inc. (NASDAQ: KRT) showcases a consistent 18% return on capital employed, outperforming its industry. Yet, as capital investment grows, analysts debate whether the sustainable packaging firm can accelerate value creation for shareholders seeking multi-bagger potential.
Despite a staggering 425% surge in earnings per share over the past year, shareholders of Grid Dynamics Holdings (NASDAQ: GDYN) have watched the stock price plummet 64%. This disconnect between robust financial performance and market valuation highlights the complex forces driving investor sentiment beyond the fundamentals.
SharpLink Gaming (NASDAQ: SBET) is drawing bullish attention from major Wall Street firms, with multiple analysts reiterating Buy ratings. The company's substantial Ethereum holdings and management's crypto expertise are seen as key drivers, even as price targets adjust to market conditions.
Innodata Inc. (NASDAQ: INOD), a data engineering and AI services firm, has been awarded a place on a critical U.S. Missile Defense Agency contract vehicle, positioning it for future task orders in defense technology development and fueling analyst optimism for its 2026 growth trajectory.
Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.
